Reports Q1 revenue $21.1M, consensus $9.78M. Revenue for the quarter was driven by a $20M development milestone from Novo Nordisk and $1.1M in Inpefa net sales. “We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said CEO Mike Exton.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals Secures New Hercules Term Loan Facility
- Lexicon Shareholders Approve New Equity Plans, Capital Increase
- Lexicon Pharmaceuticals (LXRX) Q1 Earnings Cheat Sheet
- Lexicon to present data at AAN annual meeting on Progress Phase 2b study
- Lexicon COGT reports Q1 EPS $2.07, consensus $1.74